title: Effects of basic fibroblast growth factor microspheres on angiogenesis in ischemic myocardium and cardiac function: analysis with dobutamine cardiovascular magnetic resonance tagging.
abstract: OBJECTIVE
  Therapeutic angiogenesis with angiogenic growth factors has described as one of the promising methods for collateral formation in the treatment of ischemic heart diseases. The purpose of this study is to assess the value of intramyocardial injection of slow-released basic fibroblast growth factor microspheres on angiogenesis and cardiac function in the early period of acute infarcted myocardium with dobutamine cardiovascular magnetic resonance tagging.
  
  
  METHODS
  Acute myocardial infarction was made by ligation of the left anterior descending coronary artery distal to its first diagonal branch. Immediately after coronary artery occlusion, 1 ml of saline containing 100 microg of basic fibroblast growth factor microspheres was injected into peri-infarct myocardial area in the basic fibroblast growth factor group, whereas only gelatin hydrogel microspheres with 1 ml of saline was given in control dogs. Cardiac function was evaluated by cine magnetic resonance imaging. Dobutamine cardiovascular magnetic resonance was performed at rest and during low doses of dobutamine to assess regional wall motion. Immunohistochemical study with von Willebrand factor was performed to observe angiogenesis.
  
  
  RESULTS
  Left ventricular ejection fraction improved markedly 10 and 17 days after treatment in the basic fibroblast growth factor group. The basic fibroblast growth factor group had more viable myocardium. Microvessel density was higher in the basic fibroblast growth factor group than in the control group except the first day after treatment.
  
  
  CONCLUSIONS
  Intramyocardial administration of basic fibroblast growth factor microspheres can promote the growth of microvessels and improve left ventricular function and myocardial viability in the early period of acute myocardial infarction.
authors.affiliation: Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, 15 Changlexi Road, Xi'an 710032, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Lijun
authors.initials: L
authors.lastname: Sun
authors.forename: Yi
authors.initials: Y
authors.lastname: Huan
authors.forename: Haitao
authors.initials: H
authors.lastname: Zhao
authors.forename: Jinglan
authors.initials: J
authors.lastname: Deng
mesh_terms: D000818:Animals; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D004280:Dobutamine; D004285:Dogs; D004337:Drug Carriers; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000627:therapeutic use; D020100:Hydrogels; D008279:Magnetic Resonance Imaging / Q000379:methods; D008833:Microcirculation / Q000187:drug effects; D008863:Microspheres; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D020100:Hydrogels; D016222:Fibroblast Growth Factor 2; D004280:Dobutamine